Corologic Raises Seed Funding for Cardiovascular Imaging AI

South Korean startup Corologic has successfully closed its initial seed funding round, drawing investment from prominent venture capital firms Kakao Ventures and Seoul Techno Holdings. The company, which focuses on artificial intelligence for cardiovascular imaging, aims to significantly reduce radiation exposure during critical diagnostic and interventional procedures.

The core innovation from Corologic is its proprietary AI solution, dubbed Angio-FILM. This technology addresses a persistent challenge in cardiology: the need for high-quality imaging during procedures like coronary angiography, which inherently involves significant radiation exposure for both patients and healthcare professionals. Traditional methods of reducing radiation often compromise image clarity, hindering diagnostic accuracy and procedural effectiveness.

Angio-FILM employs advanced AI-driven video frame interpolation. By analyzing sequences of X-ray fluoroscopy images captured at lower frame rates, the AI intelligently reconstructs and enhances the visual data in real-time. It achieves this by predicting intermediate frames, effectively creating a smoother, higher-frame-rate visualization of blood vessel dynamics and instrument movement. This allows clinicians to maintain crucial procedural oversight without increasing the overall radiation dose.

A key advantage highlighted by Corologic is the solution's compatibility with existing medical infrastructure. Angio-FILM is designed as an add-on system that integrates seamlessly with current angiography equipment and hospital imaging networks. Utilizing edge processing, the computational load is managed directly within the hospital environment, minimizing the need for costly equipment overhauls and simplifying adoption for healthcare facilities. This approach is particularly attractive in a market where capital expenditure for new technology can be a significant barrier.

The company's founding team brings a potent blend of clinical expertise and technological acumen. Led by CEO Kyungrae Hwang, who possesses 24 years of experience in the medical device sector, the team includes Chief Medical Officer Sihyuk Kang, a professor and interventional cardiologist from Seoul National University Bundang Hospital, and Chief Technology Officer Youngrak Choi, an expert in medical imaging AI and cardiovascular equipment. This multidisciplinary foundation is crucial for developing solutions that are both clinically relevant and technologically robust.

With this seed funding, Corologic plans to advance its product development through multi-center clinical validation studies. The company is also targeting key regulatory milestones, including obtaining clearance from South Korea's Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA) via the 510(k) pathway. Securing global quality certifications like ISO 13485 is also a priority, paving the way for widespread adoption by medical institutions worldwide.

The market for AI in medical imaging is experiencing substantial growth, driven by the demand for improved diagnostic accuracy, operational efficiency, and patient safety. Solutions that demonstrably reduce radiation exposure, like Angio-FILM, are particularly well-positioned to capture significant market share. The investment from Kakao Ventures and Seoul Techno Holdings underscores the perceived potential of Corologic to address a critical unmet need in cardiovascular care and establish itself as a leader in this specialized AI segment.